Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Glycorex Transplantation AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -98.63%.
The historical rank and industry rank for Glycorex Transplantation AB's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:O33'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -691.17 Med: -63.91 Max: 172.64
Current: -64.14
During the past 13 years, Glycorex Transplantation AB's highest ROC (Joel Greenblatt) % was 172.64%. The lowest was -691.17%. And the median was -63.91%.
FRA:O33's ROC (Joel Greenblatt) % is ranked better than 65.03% of 1324
companies
in the Biotechnology industry
Industry Median: -291.75
vs FRA:O33: -64.14
Glycorex Transplantation AB (FRA:O33) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glycorex Transplantation AB ROC (Joel Greenblatt) % Chart
FRA:O33 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Glycorex Transplantation AB's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glycorex Transplantation AB ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Glycorex Transplantation AB's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Glycorex Transplantation AB's ROC (Joel Greenblatt) % falls into.
Glycorex Transplantation AB ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -98.63% mean?
Glycorex Transplantation AB (FRA:O33) has a ROC (Joel Greenblatt) % of -98.63% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Glycorex Transplantation AB and its competitors. According to the industry distribution chart, Glycorex Transplantation AB ranks #463 out of 1324 companies in the Biotechnology industry, placing it in the top 35%.
Is Glycorex Transplantation AB's ROC (Joel Greenblatt) % too high?
Glycorex Transplantation AB's current ROC (Joel Greenblatt) % is -98.63%. Based on the distribution chart, Glycorex Transplantation AB ranks #463 out of 1324 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Glycorex Transplantation AB has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Glycorex Transplantation AB's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Glycorex Transplantation AB ranks #463 out of 1324 companies for ROC (Joel Greenblatt) %. This puts Glycorex Transplantation AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Glycorex Transplantation AB and its competitors. Glycorex Transplantation AB's current ROC (Joel Greenblatt) % is -98.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glycorex Transplantation AB stock overvalued right now?
Based on GuruFocus' analysis, Glycorex Transplantation AB (FRA:O33) is currently considered Possible Value Trap. The stock's GF Value™ is €0.14, compared to a current price of €0.09 — trading 36.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is -98.63%. Glycorex Transplantation AB's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Glycorex Transplantation AB (FRA:O33), the current ROC (Joel Greenblatt) % is -98.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glycorex Transplantation AB (FRA:O33) Overvalued in 2026?
Based on GuruFocus' analysis, Glycorex Transplantation AB stock appears to be undervalued.
The current stock price of €0.09 is trading 36.7% below its estimated GF Value™ of €0.14.
GuruFocus considers Glycorex Transplantation AB to be Possible Value Trap.
Key valuation signals for FRA:O33:
ROC (Joel Greenblatt) %: -98.63%
GF Value™: €0.14 vs. price of €0.09 (36.7% below fair value)
No single metric tells the full story. See the FRA:O33 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glycorex Transplantation AB is a medical technology company. Its main product Glycosorb ABO is used clinically in six continents to facilitate blood group incompatible transplants, especially in kidney transplants from related living donors, but also in transplantation of liver, heart, lung and stem cells. Glycosorb ABO enables grafts regardless of the blood group of donors and recipients. The product is used in extracorporeal blood treatment, that is, a blood treatment that takes place outside the body in the same way as dialysis. Its segment is research, develop, manufacture, market and sell products in the field of organ transplantation or related areas. Geographically it operates in Europe, Australia, Singapore, India, and Other countries with majority of revenue from Europe.
61GF Score
Get the complete analysis for FRA:O33
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O33 has been successfully added to your 
